Rewriting the Rules of Mitral Valve Repair
Nyra Medical is redefining transcatheter repair for functional mitral regurgitation with the Cardiac Leaflet Enhancer (CARLENTM) — a single-leaflet solution designed to preserve native valve function and expand treatment options for both TEER-suitable patients and those historically left behind.
Recognized for breakthrough innovation
Jon DeHaan Foundation Award for Innovation in Cardiology
Nyra Medical has been selected as a recipient of the Jon DeHaan Foundation Award, receiving a grant in recognition of the company’s innovative approach to transcatheter mitral valve repair. For Nyra, this recognition validates not only the promise of the CARLEN System, but also the encouraging first-in-human experience that supports our mission to expand treatment options for patients with functional mitral regurgitation (FMR).
Jon DeHaan Foundation Award Interview at EuroPCR
Dr. Susheel Kodali, Tom DeHaan
Founded to Redefine Mitral Valve Repair
Nyra Medical was founded in 2019, based on intellectual property developed at Emory University by Dr. Murali Padala. The company licensed its core technology, CARLEN, in 2021 and raised Series A in 2022 supported by experienced medtech investors. In 2023, industry veteran Lori Chmura joined as CEO to lead Nyra Medical through First-in-Human studies and global clinical research.
